A Recombinant Immunotoxin Against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-12-0336
Full Text
Open PDFAbstract
Available in full text
Date
November 6, 2012
Authors
Publisher
American Association for Cancer Research (AACR)